Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA ... and Novo Nordisk’s semaglutide—by improving ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The impetus for the new report was a patient at the University of Utah Health who developed NAION 1 day after starting semaglutide ... possible links between GLP-1 receptor agonists and NAION.